Abstract
Recent understanding in pathophysiological mechanisms of spinal cord and spinal root injuries has facilitated the development of new strategies to promote neural repair. Gene therapy approaches have been viewed as the ideal means to achieve long-term local delivery of therapeutic molecules in the central nervous system (CNS). Ex vivo gene delivery offers the additional advantage of providing cellular support for regenerating axons. In this review, we summarize the studies on viral vector-mediated gene delivery to spinal cord in animal models, both in vivo and ex vivo. Most of the studies reported so far are aimed at delivery of various growth factors, such as neurotrophins and neuropoietic cytokines. Other molecules tested include those that interfere with intracellular processes to prevent cell death, or increase intrinsic regenerating state of injured neurons, or modify the CNS environment to make it permissive for axon growth. Several different combinatorial strategies involving gene delivery are also discussed as it has been recognized that successful neural repair may require the synergistic actions of multiple therapeutic managements.
Keywords: Axonal regeneration, cell therapy, gene therapy, neurotrophic factor, spinal cord injury, viral vector, pathophysiological, CNS, Exogenous genetic, neurons, antibodies
Current Gene Therapy
Title: Gene Therapy Approaches for Neuroprotection and Axonal Regeneration after Spinal Cord and Spinal Root Injury
Volume: 11 Issue: 2
Author(s): Xuenong Bo, Dongsheng Wu,, John Yeh and Yi Zhang
Affiliation:
Keywords: Axonal regeneration, cell therapy, gene therapy, neurotrophic factor, spinal cord injury, viral vector, pathophysiological, CNS, Exogenous genetic, neurons, antibodies
Abstract: Recent understanding in pathophysiological mechanisms of spinal cord and spinal root injuries has facilitated the development of new strategies to promote neural repair. Gene therapy approaches have been viewed as the ideal means to achieve long-term local delivery of therapeutic molecules in the central nervous system (CNS). Ex vivo gene delivery offers the additional advantage of providing cellular support for regenerating axons. In this review, we summarize the studies on viral vector-mediated gene delivery to spinal cord in animal models, both in vivo and ex vivo. Most of the studies reported so far are aimed at delivery of various growth factors, such as neurotrophins and neuropoietic cytokines. Other molecules tested include those that interfere with intracellular processes to prevent cell death, or increase intrinsic regenerating state of injured neurons, or modify the CNS environment to make it permissive for axon growth. Several different combinatorial strategies involving gene delivery are also discussed as it has been recognized that successful neural repair may require the synergistic actions of multiple therapeutic managements.
Export Options
About this article
Cite this article as:
Bo Xuenong, Wu, Dongsheng, Yeh John and Zhang Yi, Gene Therapy Approaches for Neuroprotection and Axonal Regeneration after Spinal Cord and Spinal Root Injury, Current Gene Therapy 2011; 11 (2) . https://dx.doi.org/10.2174/156652311794940773
DOI https://dx.doi.org/10.2174/156652311794940773 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets 5-Nitro-Thiophene-Thiosemicarbazone Derivatives Present Antitumor Activity Mediated by Apoptosis and DNA Intercalation
Current Topics in Medicinal Chemistry Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Effect of Selenium Enrichment of <i>Lenzites betulinus</i> and <i>Trametes hirsuta</i> Mycelia on Antioxidant, Antifungal and Cytostatics Potential
Current Pharmaceutical Biotechnology Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?
Current Medicinal Chemistry Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets Modelling and Measuring Redox Cycling and Cytotoxicity of Quinones
Drug Metabolism Letters The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action
Recent Patents on Anti-Cancer Drug Discovery Proteomics Annotation of Lipid Rafts Modified by Virus Infection
Combinatorial Chemistry & High Throughput Screening Synthesis and Biological Activity of Quinoxalone Derivatives as BRD4 Bromodomain Inhibitors
Letters in Drug Design & Discovery Interferon-α Treatment in Systemic Mastocytosis
Current Drug Targets The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Patents in Cancer Stem Cells
Recent Patents on Biomarkers